Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • swaraj
    Member
    • Feb 2012
    • 50

    #1

    Cufflinks RABT assembly

    Dear All,

    I have run cufflinks with "-g" (RABT assembly) and "--no-faux-reads" option on a single end, un-stranded sequencing data. As reference I have provided a pooled gtf file comprising of refseq, ensembl and mRNA transcripts. I observed that cufflinks builds many transcripts on the basis of the reference which do not have any read coverage or very less read coverage.

    I would like to avoid this situation. I thought using the "--no-faux-reads" solves my problem but it does not. I would like to use the RABT assembly with a reference file but want to disallow cufflinks from building transcripts for which there are no mapped reads.
  • arvid
    Senior Member
    • Jul 2011
    • 156

    #2
    You could simply remove the transcripts without read coverage in the end, instead.

    Comment

    • swaraj
      Member
      • Feb 2012
      • 50

      #3
      Yes thats what I did, but I still have many transcripts built from reference gtf which have like 0.1-0.5 coverage on their exons. I am not sure how to treat them as cufflinks has build them because they were present in the reference gtf.

      I am looking towards identifying novel intergenic non-coding transcripts, many of which are build by cufflinks using reference intergenic unannotated mRNA from the gtf. Hence I am not sure whether to take such transcripts at all.

      Comment

      • arvid
        Senior Member
        • Jul 2011
        • 156

        #4
        So if you look for novel transcripts, I guess you would like to filter out all known features, wouldn't you? (with e.g. BEDTools "intersectBed -v") Regardless of their coverage? I'm still a bit confused about what your actual problem is then...

        Comment

        • swaraj
          Member
          • Feb 2012
          • 50

          #5
          Yes I would like to filter out known features, but keep those mRNA features which do not overlap a protein coding gene. In this regard I get many reported transcripts which are build from reference mRNAs but do not overlap protein coding genes. For me they are putative stage specific intergenic transcripts. What I am not able to resolve is whether I should consider their presence even after a very low coverage. I suspect most of them have been built by cufflinks simply because they were present in the reference gtf file.

          Comment

          • arvid
            Senior Member
            • Jul 2011
            • 156

            #6
            I guess that depends on what you would like to do downstream with the candidates. I'd simply remove all really-low-coverage features (something like less than 5 reads aligned, or so, or where less than 25 % is covered at all), if there are tons of them, and focus on what's left. Then I'd label them according to "previously described" or "completely novel", and carry on according to the interest of the study (typically differential expression analysis in my case).

            Comment

            • swaraj
              Member
              • Feb 2012
              • 50

              #7
              Thanks a lot. This was quite helpful.

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                by SEQadmin2



                CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                Despite this, “CRISPR helped turn genome editing from a specialized technique into
                ...
                07-31-2026, 11:01 AM
              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Today, 10:35 AM
              0 responses
              3 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 08-06-2026, 07:41 AM
              0 responses
              23 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 08-03-2026, 10:13 AM
              0 responses
              40 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-31-2026, 02:55 AM
              0 responses
              46 views
              0 reactions
              Last Post SEQadmin2  
              Working...